Preparation and characterization of amoxicillin mucoadhesive microparticles using solution-enhanced dispersion by supercritical CO 2

Journal of Microencapsulation

Volumn 29, Issue 4, 2012, Pages 398-408

  Patel, Jayvadan ^a   Patil, Priyanka ^b  

^a NOOTAN PHARMACY COLLEGE   (India)

^b M S UNIVERSITY OF BARODA   (India)

Author keywords

Amoxicillin; H. pylori; Microparticles; Mucoadhesive; Supercritical CO 2

Indexed keywords

AMOXICILLIN; BUFFER; CARBON DIOXIDE; CHITOSAN; HYDROCHLORIC ACID; POLYMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DISPERSION; DRUG EFFECT; DRUG STABILITY; GASTROINTESTINAL TRACT; HELICOBACTER PYLORI; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROENCAPSULATION; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PH; POWDER; RAT; SCANNING ELECTRON MICROSCOPE; STOMACH MUCOSA; X RAY POWDER DIFFRACTION;

ADHESIVENESS; AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CARBON DIOXIDE; CHITOSAN; DRUG COMPOUNDING; DUODENAL ULCER; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MALE; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDER DIFFRACTION; RATS; RATS, WISTAR; SOLUTIONS; STOMACH ULCER;

EID: 84861033977     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.655329     Document Type: Article

References (54)

1. Atherton JC, Cockayne A, Balsitis M, Kirk GE, Hawley CJ, Spiller RC. Detection of the intragastric sites at Helicobacter pylori evades treatment with amoxicillin and cimetidine. Gut, 1995;36:670-4.
2. Axon AT. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol, 1994;29:16-23.
3. Berton M, Benimetskaya L, Allemann E, Stein CA, Gurny R. Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization. Eur J Pharm Biopharm, 1999;47:119-23.
4. Blaser M. Ecology of helicobacter pylori in the human stomach. J Clin Invest, 1997;100:759-62.
5. Buzas GM, Szekely E. Eradication of Helicobacter pylori in peptide ulcer patients. Orv Hetil, 1999;140:121-4.
6. Byrappa K, Ohara S, Adschiri T. Nanoparticles synthesis using supercritical fluid technology-Towards biomedical applications. Adv Drug Delivery Rev, 2008;60:299-27.
7. Chadha R, Kashid N, Jain DV. Kinetic studies of the degradation of an aminopenicillin antibiotic in aqueous solution using heat conduction microcalorimerty. J Pharm Pharmcol, 2003;55:1495-503.
8. Chen AZ, Pu XM, Kang YQ, Liao L, Yao YD, Yin GF. Preparation of 5-fluorouracil-poly(L-lactide) microparticles using solution-enhanced dispersion by supercritical CO2, Macromol Rapid Commun, 2006;27:1254-59.
9. Chen AZ, Pu XM, Kang YQ, Liao L, Yao YD, Yin GF. Study of poly(L-lactide) microparticles based on supercritical CO2. J Mater Sci-Mater Med, 2007;18:2339-45.
10. Chickering D, Jacob J, Mathiowitz E. Bioadhesive microspheres: II. Characterization and evaluation of bioadhesion involving hard, bioerodiable polymers and soft tissue. Reactive Polym, 1995;25:198-206.
11. Cooreman MP, Krausgrill P, Hengels KJ. Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob Agents Chemother, 1993;37:1506-9.
12. Erach PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxicillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother, 1997;39:5-12.
13. Forman D, Newell F, Fullerton J, Yarnell A, Stacey N, Wald S. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. Br Med J, 1991;302:302-5.
14. Forman D, Webb P, Personnet JH. Pylori and gastric cancer. Lancet, 1994;343:243-4.
15. Giacomo F, Marinano L, Silvana M, Domenico S, Gaetano G. Amoxicillinloaded polyethylcyanoacrylate nanoparticles: Influence PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials, 2001;22:2857-65.
16. Gisbert J, Pajares J. Helicobacter pylori therapy: First-line options and rescue regimen. Dig Dis, 2001;19:134-43.
17. Hakuta Y, Hayashi H, Arai K. Fine particle formation using supercritical fluids. Solid State Mater Sci, 2003;7:341-51.
18. Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustainedrelease floating dosage form of amoxicillin trihygrate. Int J Pharm, 1992;86:79-88.
19. Hombreiro-Perez M, Siepmann J, Zinutti C, Lamprecht A, Ubrich N, Hoffman M. Nondegradable microparticles containing a hydrophilic and/or a lipophilic drug: Preparation, characterization and drug release modeling. J Control Rel, 2003;88:413-28.
20. Hombreiro-Perez M, Zinutti C, Lamprecht A, Ubrich N, Astier A, Hoffma M. The preparation and evaluation of poly(ε"-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug. J Control Rel, 2000;65:429-38.
21. Jenks P, Edwards D. Metronidazole resistance in Helicobacter pylori. Int J Antimicrob Agents, 2002;19:1-7.
22. Jung J, Perrut M. Particle design using supercritical fluids: Literature and patent survey. J Supercrit Fluids, 2001;20:179-19.
23. Kang YQ, Yin GF, Ouyang P, Huang ZB, Yao YD, Liao XM, Chen AZ, Pu XM. Preparation of PLLA/PLGA microparticles using solution enhanced dispersion by supercritical fluids (SEDS). J Colloid Interface Sci, 2008;322:87-94.
24. Kawabami E, Ogata SK, Portorreal AC. Triple therapy with clarithromycin amoxicillin and omeprazole for Helicobacter pylori in eradication in children and adolescents. Arq Gastroenterol, 2001;38:203-6.
25. Korsemeyer R, Gurny R, Peppas N. Mechnisums of solute release from porous hydrophilic polymers. Int J Pharm, 1983;15:25-35.
26. Kwon D, Kim J, Lee M, Yamaoka M, Kato M, Osato M, El-Zaatari F, Graham D. Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother, 2000;44:3203-5.
27. Lehr CM, Bowstra JA, Tukker JJ, Junginger HE. Intestinal transit of bioadhesive microspheres in an in situ loop in the rat. J Contr Rel, 1990;13:51-62.
28. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm, 1992;78:43-8.
29. Lin CK, Hsu PI, Lai KH. One-week quadruple therapy is an effective salvage regiment for Helicobacter pylori infection in patients after failure of standard triple therapy. J Clin Gastroenterol, 2002;34:547-51.
30. Lorenzo-Lamosa ML, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Rel, 1998;52:109-18.
31. Magraud F, Lamouliatte H. Helicobacter pylori and duodenal ulcers. Dig Dis Sci, 1992;37:769-72.
32. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. European Helicobacter pylori study group (EHPSG). Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Theor, 2002;16:167-80.
33. Martín A, Cocero MJ. Micronization processes with supercritical fluids: Fundamentals and mechanisms. Adv Drug Delivery Rev, 2008;60: 339-50.
34. Mascher C, Kikuta C. Determination of amoxicillin in human serum and plasma by high-performance liquid chromatography and on-line postcolumn derivatisation. J Chromatogr A, 1998;182:221-6.
35. Munday DL, Cox PL. Compressed xanthan and karaya gum matrices hydration, erosion and drug release mechanisms. Int J Pharma, 2000; 203:179-92.
36. Nagahara N, Akiyama Y, Nako M, Tada M, Kitano M, Ogawa Y. Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori. Antimicrob Agent Chemother, 1998;42:2492-4.
37. Nixon JR, 1983. Release characterization of microcapsules. In: Lim F, ed. Biomedical applications of microcapsulation. Boca Raton, FL: CRC Press, p. 1227.
38. Ogwal S, Xide TU. Bioavailability and stability of erythromycin delayed release tablets. Afr Health Sci, 2001;2:90-6.
39. Osato M, Reddy S, Reddy R, Penland R, Malaty H, Graham D. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med, 2001;161:1217-20.
40. Patel JK, Chavda JR. Formulation and evaluation of stomach-specific amoxicillin-loaded carbopol-934P mucoadhesive microspheres for anti-Helicobacter pylori therapy. J. Microencapsulat, 2009;26:365-76.
41. Patel JK, Patel MM. Stomach specific anti-Helicobacter Pylori therapypreparation and evaluation of amoxicillin loaded chitosan mucoadhesive microspheres. Curr Drug Deliv, 2007;4:41-51.
42. Ranga R, Devi KD, Buri P. Cellulose matrices for zeroorder release of soluble drugs. Drug Dev Ind Pharm, 1988;14:2299-2320.
43. Reverchon E. Supercritical antisolvent precipitation of micro-and nanoparticles. J Supercrit Fluids, 1999;15:1-21.
44. Ritger P L, Peppas NA. A simple equation for description of solute release: I. Fickian and non-Fickian release from nonswellable devices in the form of slabs, spheres, cylinders or discs. J Control Rel, 1987a;5:23-36.
45. Ritger P L, Peppas NA. A simple equation for description of solute release: II. Fickian and anomalous release from swellable devices. J Control Rel, 1987b;5:37-42.
46. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, Dhawan S. Chitosan microspheres as a potential carrier for drugs. Int J Pharm, 2004;274:1-33.
47. Suleymanlar I, Tuncer M, Tugrul Sezer M, Erttugrul C, Sarikaya M, Fevzi Ersoy E, Isitan F, Yakupoglu G, Suleymanlar G. Response to triple treatment with omeprazole, amoxicillin and clarithromycin for Helicobacter pylori infections in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial, 1999;15:79-81.
48. Vakil N, Cutler A. Ten-day triple therapy with ranitidine, bismuthcitrate, amoxicillin and clarithromycin in eradicating Helicobacter pylori. Am J Gastroenterol, 1999;94:1197-9.
49. Vega-Gonzalez A, Subra-Paternault P, Lopez-Periago AM, Garcia-Gonzalez CA, Domingo C. Supercritical CO2 antisolvent precipitation of polymer networks of L-PLA, PMMA and PMMA/PCL blends for biomedical applications. Eur Polym J, 2008;44(4):1081-94.
50. Wang YL, Dave RN, Pfeffer R. Polymer coating/encapsulation of nanoparticles using a supercritical anti-solvent process. J Supercritic Fluids, 2004;28:85-99.
51. Wang YL, Pfeffer R, Dave R, Enick R. Polymer encapsulation of fine particles by a supercritical antisolvent process. AIChE J, 2005;51: 440-55.
52. Wang YL, Wang YP, Yang J, Pfeffer R, Dave R, Michniak B. The application of a supercritical antisolvent process for sustained drug delivery. Powder Technol, 2006;164:94-102.
53. Warren JR, Marshall B. Unified curved bacilli on gastric epithelium in active chronic gastritis. Lancet, 1983;321:1273-5.
54. Wu H, Shi XD, Wang HT, Liu JX. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother, 2000;46:121-3.